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Background: Dengue virus (DENV) still poses a global public health threat, and no vaccine or antiviral therapy is
currently available. Antibody plays distinct roles in controlling DENV infections. Neutralizing antibody is protective
against DENV infection, whereas sub-neutralizing concentration of antibody can increase DENV infection, termed
antibody-dependent enhancement (ADE). Plaque-based assay represents the most widely accepted method measuring
neutralizing or enhancing antibodies.
Results: In this study, a novel reporter virus-based system was developed for measuring neutralization and ADE activity.
A stable Renilla luciferase reporter DENV (Luc-DENV) that can produce robust luciferase signals in BHK-21 and K562 cells
were used to establish the assay and validated against traditional plaque-based assay. Luciferase value analysis using
various known DENV-specific monoclonal antibodies showed good repeatability and a well linear correlation with
conventional plaque-based assays. The newly developed assay was finally validated with clinical samples from
infected animals and individuals.
Conclusions: This reporter virus-based assay for neutralizing and enhancing antibody evaluation is rapid, lower
cost, and high throughput, and will be helpful for laboratory detection and epidemiological investigation for
DENV antibodies.
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The four serotypes of dengue virus (DENV) belong to
the genus Flavivirus within the family Flaviviridae [1].
The clinical manifestations of DENV infections cover a
wide range of symptoms, from mild dengue fever (DF)
to severe life threatening dengue hemorrhagic fever
(DHF) and dengue shock syndrome (DSS) [2]. Com-
monly, DHF/DSS is associated with sequential DENV
infection by different serotypes [3,4]. Annually, 50 to
100 million people in over 100 countries are infected
with DENV and DHF/DSS can be fatal in up to 5% of
affected individuals. No vaccine or specific antiviral
drugs is currently available.
DENV is a typical positive-sense, single-stranded RNA
virus. The genome is about 11 kb in length and encodes* Correspondence: qincf@bmi.ac.cn
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structural proteins (NS1, NS2A, NS2B, NS3, NS4A,
NS4B, and NS5). Neutralizing antibody is predominantly
induced against E protein, and laboratory and clinical
studies have demonstrated that protection of animals
or individuals from DENV infection is best correlated
to titer of neutralizing antibody (>1:10). However, pre-
existing sub-neutralizing concentration of antibody or
non-neutralizing antibody was also evidenced to enhance
DENV infection in Fc gamma Receptor (FcγR) - positive
cells and appears to be a risk factor for severe diseases.
This phenomenon is known as antibody-dependent
enhancement (ADE) infection [5,6]. Thus, human anti-
bodies are believed to play distinct roles in controlling
DENV infection. It is important to characterize anti-
body with neutralizing or enhancing activities against
DENV for both basic and applied research.
Currently, plaque-based analysis is the most widely
accepted method measuring neutralizing or enhancing
antibodies [7] and has been recommended by the Worldtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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time-consuming and labor intensive, and not suitable for
large-scale samples analysis. Further, plaque-based assay
can only be performed in cells that permit plaque forming
and quantified by an operator-error prone manual readout
based on the number of plaques. There is a great need of
novel technology for characterizing DNEV neutralizing
and enhancing antibodies in a simple, rapid, and high-
throughput manner [8].
Recently, we have developed a stable luciferase reporter
DENV (Luc-DENV) for antiviral high-throughput screen-
ing [9]. In this study, we aim to adapt the Luc-DENV for
anti-DNEV neutralizing and enhancing antibodies evalu-
ation. This newly developed reporter virus-based assay is
validated using various known monoclonal antibodies
(mAbs) and clinical samples from infected animal and
patients, demonstrating well correlation with the traditional
plaque-based assays.Results
Development of Luc-based neutralizing assay
The Luc-DENV was developed by engineering the Renilla
luciferase gene into the capsid-coding region by reverse
genetic technology [9]. We have shown that Luc-DENV
replicates efficiently in both mammalian and mosquito
cells with high stability. As shown in Additional file 1:
Figure S1 and Additional file 2: Figure S2, increasing
amounts of luciferase signal were observed from 24 to
96 h post-infection in Luc-DENV infected BHK-21 and
K562 cells.
To adapt Luc-DENV for neutralizing assay, we firstly
assayed three identified neutralizing mAbs 4G2 [10],
2B8 [11] and 2A10G6 [11] by using plaque-based and
Luc-based assay, respectively. Standard PRNT was per-
formed in 12-well plates using 10-fold dilution of each
mAb. The results showed that all three mAbs significantly
reduced the numbers of plaques in a dose-dependent
manner (Figure 1,ABC, right ordinate). The PRNT50 of
4G2, 2B8 and 2A10G6 was 8.55, 0.45 and 0.35 μg/mL,
respectively. The RLU based assay was performed in
the 12-well plate using the same dilutions of each mAb.
The results demonstrated that all three mAbs significantly
decreased RLU in a dose-dependent manner (Figure 1,
ABC, left ordinate). LRNT50 of three mAbs calculated
from a fitting curve were 6.80, 0.86 and 0.26 μg/mL, re-
spectively, which was of the same order of magnitude
with PRNT50. An unrelated mAb against EV71 showed
no neutralization for both plaque and Luc-based assay
(data not shown). Data fitting was made between values
above. As expected, a linear correlation (R2 > 0.95) was
demonstrated between PFU and RLU assay, and the
linear equation between RLU and PFU is calculated
as RLU = 86.74 PFU + 2256 (Figure 1D). Our resultssupported the application of Luc-based assay for
neutralization antibodies against DENV.
Development of Luc-based ADE assay
To develop the Luc-DENV for ADE assay, K562 cells
were infected with Luc-DENV in the presence of serial
10-fold dilutions of 2A10G6. The viral titers in the
supernatants were measured by standard plaque-based
assay and Rlu-based assay, respectively. The results
showed that the viral yield was markedly enhanced in
the presence of 2A10G6 at dilutions ranging from
100 μg/mL to 0.01 μg/mL, and the peak enhancing was
8.19-fold at a concentration of 1.00 μg/mL (Figure 2A,
right ordinate). The RLU assay showed similar pattern
of enhancing, and the peak enhancing was 5.06-fold
at a concentration of 1.00 μg/mL (Figure 2A, left ordinate),
of the similar magnitude with plaque based assay. To get a
linear equation between RLU and PFU, the results obtained
with 2A10G6 were plotted on a scatter graph (Figure 2B).
As expected, the enhancing antibody titer determined
by RLU was linear correlated to PFU (R2 > 0.95), and
the linear equation between RLU and PFU obtained
was RLU = 3.657PFU + 1152, similar to the neutralizing
equation. Together, these results indicated that this novel
reporter system using Luc-DENV is readily for antibody
neutralizing and enhancing assay with equivalent reli-
ability to the conventional PFU-based assays.
Validate the use of the assay with clinical samples
Finally, this RLU based assay was validated with clin-
ical samples from immunized monkeys and patients.
Neutralization assays were performed using 2-fold serial
dilution sera in BHK-21 cells. For enhancing assay, sera
were 10-fold serial dilution and assay was performed in
K562 cells. Sera from Rhesus Monkeys (#175, #052) im-
munized with a live attenuated DENV-2 showed strong
neutralizing activity, and LRNT50 was calculated to 100
and 70, respectively (Figure 3). Negative control (#NS)
from healthy monkey showed no neutralizing activity as
expected. Luc-based enhancement assay showed that both
sera from immunized monkeys could significantly en-
hanced Luc-DENV replication at dilutions from 2 × 10-2
to 10-5 (#175), and 10-1 to 10-5 (#52), respectively. The
enhancing activity of #175 is higher than that of #52. No
enhancement was observed for #NS as expected (Figure 4).
Three convalescent sera from DF patients (#19-20,
#37-20, #37-30) were validated with the newly developed
assay in K562 cells. As shown in Figure 5, all three sam-
ples were able to enhance DENV infection at dilutions
from 2 × 10-2 to10-4 (#19-20), 10-2 to10-5 (#37-20), and 10-1
to10-4 (#37-30), respectively. Negative control (#NC) from
healthy adult in varying dilutions showed no impact on
RLU as expected. Meanwhile, serum #19-20 and #37-20
showed strong neutralizing activities at a dilution of 10-2 or
Figure 1 Comparison of the new and conventional antibody neutralization assay system. Neutralization activities mediated by various
concentrations of mAbs (A: 4G2, B: 2B8, C: 2A10G6) specific for E protein of DENV in BHK-21 cells were performed with the new (square) and
conventional (round) antibody neutralization assay system. Error bars indicate the standard deviations from two independent experiments.
(D) Linear correlation between RLU and PFU values for neutralization assay.
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dilution separately, whereas no neutralizing activity can be
observed in serum #37-30 at detected dilutions. Together,
these results indicate that the Luc-based assay is suitable
for detecting both neutralization and ADE activity of im-
mune sera from vaccinated or infected individuals.Figure 2 Comparison of the new and conventional enhancing assay s
in K562 cells with Luc-DENV. Luciferase activities (square) and PFU (round)
K562 cells. Error bars indicate the standard deviations from two independe
enhancing assay.Discussion
A reliable, rapid, and high-throughput assay for DENV
neutralization antibodies is critical for laboratory and
clinical studies of DENV infection and vaccine. Consid-
ering the limitations of plaque based assay, some novel
methods for neutralizing assays have been describedystem. (A) Enhancing assay of anti-E protein mAb 2A10G6 to DENV-2
were measured at 72 h after incubating virus–antibody complex with
nt experiments. (B) Linear correlation between RLU and PFU values in
Figure 3 Enhancing activity assay of monkey anti-DENV sera using the new assay system. Samples #175 and #052 were obtained from
subjects positive to DENV, and #NS (negative serum) was a sample from healthy subject as a negative control. Sera in various dilutions were mixed
with Luc-DENV and incubated for 72 h. Luciferase activities were measured in lysed K562 cells to assay enhancing activities. Error bars indicate
the standard deviations from two independent experiments.
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ELISPOT based neutralization test, demonstrating a well
correlation with the conventional PRNT assay [19].
Pseudo infectious DENV reporter virus particles (RVP)
carrying green fluorescent protein (GFP) reporter were
also used to measure neutralization antibodies with rap-
idity, stability and reproducibility [15,16,20]. Infection
with RVP could be monitored by the GFP signals using
flow cytometry. However, GFP is not suitable for real-
time quantification, and production of RVP requires spe-
cial cell lines and replicon based plasmids. Live reporter
virus carrying luciferase reporter replicates almost the
same as wild type virus, representing a more advanced
tool. Many reporter viruses, including SARS-related cor-
ona virus, human hepatitis C virus, parainfluenza virus,
HIV, adenovirus, have been described and well appliedFigure 4 Neutralization assay for monkey sera using the new assay sy
with 50 PFU Luc-DENV, after incubating for 24 h, mixtures were added to BHK
BHK-21 cells after 48 h incubating to assay neutralization activities. Error bars ifor antiviral screening, live imaging, or function studies
[21-25]. Live reporter DENV engineering a reporter gene
at the capsid gene has been developed [26]. Recently, we
described the stable luciferase DENV reporter virus Luc-
DENV and used it for high-throughput screening for
antiviral drugs [9]. In this study, we demonstrated the
utility of Luc-DENV for measuring neutralization and
enhancing antibodies. Using three identified neutralizing
mAbs, Luc-based assay showed well correlation with the
PRNT-based assay. 4G2 and 2B8 are both IgG1 isotype
mAbs, and 2A10G6 belongs to IgG2a isotype. 2B8 rec-
ognizes the domain III of DENV E protein and inhibit
viral binding, while 2A10G6 and 4G2 inhibit fusion. All
three mAbs were active in inhibiting plaque forming and
Luc expression in Luc-DNEV infected Vero cells. The value
of PRNT50 and LRNT50 are well correlated (R2 > 0.95).stem. Samples #175 and #052 and #NS in various dilutions were mixed
-21 cells in 12-well plate. Luciferase activities were measured in lysed
ndicate the standard deviations from two independent experiments.
Figure 5 Enhancing activity assay for patient sera using the new assay system. Samples #19-20, #37-20 and #37-30 were obtained from
Chinese subjects positive to DENV, with a sample from healthy people #NS as a negative control. Sera in various dilutions were mixed with
Luc-DENV and incubated for 72 h, and luciferase activities were measured in lysed K562 cells to assay enhancing activities. Error bars indicate
the standard deviations from two independent experiments.
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of clinical samples from vaccinated animals and infected
patients.
ADE infection of DENV has been well demonstrated
in vitro and in vivo, and represents one of the major
impediments against vaccine development. Previously,
different methods based on infection rate [27,28], pro-
geny viral yield [29], and number of infectious centers
[30,31] have been reported to measure the ADE activity
in FcR expressing cells including K562, U937 or THP-1
cells. The FACS analysis has been commonly used to
quantify the infection rate in C6/36 cells, Raji B, and hu-
man peripheral blood mononuclear cells [32,33]. Progeny
viral yield can be detected either by conventional plaque
assay or NS1-based ELISA [34], ELISPOT [19], and real-
time RT-PCR [32]. Recently, Moi et al. [35] successfully
established stable BHK-21 cell lines that express FcRIIA,
which facilitate both neutralization and ADE assay.
The plaque based assay determined the infectious par-
ticles released from virus-infected cells, whereas theRLU based assay described in this study offered a simple
method which detected viral protein expression in cells.
Linear correlation was established between the two as-
says for both neutralization and ADE assays (Figure 1D
and Figure 2B). The newly developed assay method is
comparable to the traditional plaque assay, with some
unique advantages. First, this Luc-based assay is more
substantial and time saving. The conventional plaque
test used 12-well plates and 5–7 days observation for the
plaque forming, the new test is compared performing
the same protocol involved 24-well plates and cost no
more than 2 days. Second, this new assay method has a
more wide-range scope of application with high repeti-
tiveness and reliability. Luc-DENV replicates well in
multiple cells including BHK-21, K562, Vero and THP-1
and A549 cells, and luciferase activity can also be
detected stably in various cells. Neutralization and ADE
assays can be performed in the same cells [34]. Third,
this new assay method is easy to adapt for a high-
throughput manner [9], which is of critical importance
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trials of dengue vaccine.
Conclusions
Together, we establish a novel reporter system for neu-
tralizing and enhancing antibody assay against DENV by
using an engineered DENV stably expressing Renilla lucif-
erase. The newly developed assay described here is rapid,
low-cost, and time-saving, providing a useful tool for both
basic research and epidemiological investigation.
Methods
Cells, virus and antibodies
Baby hamster kidney cells (BHK-21) and African green
monkey kidney (Vero) cells were cultured in Dulbecco’s
Modified Essential Medium (DMEM; Invitrogen) supple-
mented with 10% fetal bovine serum (FBS; Hyclone) and
1% penicillin–streptomycin at 37°C in a 5% CO2. Human
erythroleukemic K562 cells were maintained in RPMI
1640 medium (Invitrogen) supplemented with 10% FBS
(GIBCO) at 37°C in a 5% CO2. The reporter Luc-DENV
has been previously described [9] and was prepared and
tittered in Vero cells. The following characterized mono-
clonal antibodies (mAbs) against DENV were used in
this study: 4G2, 2B8 and 2A10G6.
Clinical samples
Serum samples were collected from Rhesus monkeys
(#175, #052) immunized with a single dose of a live at-
tenuated DENV (unpublished data), and serum from the
unimmunized animal was set as negative control (#NS).
Human convalescent sera from DF patients (#19-20,
#37-20, #37-30) and control serum negative for DENV
(#NC) were from Guangzhou No.8 People’s Hospital,
Guangzhou, China. All samples were inactivated at 56°C
for 30 min before assay.
Plaque reduction neutralization test (PRNT)
PRNT were performed as previously described [12].
Briefly, 2 × 105 cells/well of BHK-21 cells were seeded
into 12-well plates and incubated overnight. 100 μl seri-
ally diluted antibody samples were mixed with an equal
volume of Luc-DENV containing 30 PFU. After 1 h in-
cubation, 200 μL of antibody-virus mixture was added to
BHK-21 cell monolayer in 12-well plates for another 1 h.
Next, the supernatant was removed, and cells were
overlaid with 1 mL of 1.0% (w/v) agarose (Promega) in
DMEM containing 4% FBS. After further incubation at
37°C for 4 days, the overlay was removed, and cells were
fixed with 4% formaldehyde for 30 min, and stained with
1% (w/v) crystal violet. DMEM served as negative control,
and each sample was assayed in triplicate. Plaques were
counted and PRNT50 is defined as the antibody dilutionresulting in 50% plaque reduction referred to negative
control.Luc-base neutralization assay
Luc-based neutralization assay was performed in 12-well
plates, and the procedure was similar to the conven-
tional PRNT assay. Briefly, virus-antibody mixture was
added to BHK-21 cells in 12-well plates and adsorbed
for 1 h at 37°C. Supernatant was removed and 1 mL
DMEM-2% FBS was replenished onto cells. After 48 h
incubation at 37°C, the supernatant was removed, cells
were lysed with 250 μl lysates (Promega) per well for
15 minutes. 50 μl lysed suspension was assayed for en-
zyme activities after adding 100 μl substrate reagent.
Data was collected using a continuous-read luminometer
(GLOMAX 96 Microplate Luminometer, Promega) inte-
grated over 10 seconds with a 2 second delay. Medium
served as negative control, each sample was assay in
triplicate. The antibody dilution resulting in 50% reduc-
tion of RLU value referred to the negative control was
defined as LRNT50.Plaque-based enhancement assay
The protocol for ADE assay has been previously described
[36]. Briefly, pre-formed antibody-DNEV complex were
prepared by incubating serially 10-fold diluted antibody
with Luc-DENV at MOI of 0.5 in 37°C before applying
to 1 × 105 K562 cells in 12-well plates. Cells were incu-
bated for additional 72 hours, and the virus titer in the
supernatant was titrated by standard plaque assay on
BHK-21 cells.Luc-based enhancement assay
The Luc-based ADE assay was operated similar with
plaque-based enhancement assay as above described in
12-well plates. Serial dilutions of antibodies mixed with
Luc-DENV were incubated for 72 hours on K562 cells,
cell lysates were then subjected to luciferase activities
assay as described above. The enhancing activity was
evaluated by comparing the RLU value from cells har-
boring antibody-Luc-DENV complex and that from cells
harboring Luc-DENV alone.Statistical analysis
All statistical analyses were performed using SPSS
13.0. Graphs were performed using the Prism software
(GraphPadPrism5, San Diego, CA). The data were pre-
sented as means plus standard deviations from there
independent experiments. A P value < 0.05 was considered
statistically significant.
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Additional file 1: Figure S1. Growth curve of Luc-DENV on BHK-21
cells expressed by luciferase activity. Cells were infected with virus at MOI
of 0.5, collected and lysed at the indicated time points to measure the
luciferase activities. Each data point represents the mean obtained in
three separate assays with SD (indicated by bars).
Additional file 2: Figure S2. Growth curve of Luc-DENV on K562 cells
expressed by luciferase activity. Cells were infected with virus at MOI of 0.5,
collected and lysed at the indicated time points to measure the luciferase
activities. Each data point represents the mean obtained in three separate
assays with SDs (indicated by bars).
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